Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg

References

• Mohty M, Terpos E, Mateos MV, et al. EMMOS investigators. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401–e419.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25:1–12.
   PubMed Web of Science ®Google Scholar
• Arnall J, Maples K, Harvey R, et al. Daratumumab for the treatment of multiple myeloma: a review of clinical applicability and operational considerations. Ann Pharmacother. 2022;56(8):927–940.
   PubMed Web of Science ®Google Scholar
• Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30(2):399–408.
   PubMed Web of Science ®Google Scholar
• Martin T, Corzo K, Chiron M, et al. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019;8(12):1522.
   PubMed Web of Science ®Google Scholar
• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107.
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos M-A, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361–2371.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309–322.
   PubMed Web of Science ®Google Scholar
• Garcia JN, Eufemiese RA, Storti P, et al. Role of 1q21 in multiple myeloma: from pathogenesis to possible therapeutic targets. Cells. 2021;10(6):1360.
   PubMed Web of Science ®Google Scholar
• Walker B, Wardell C, Brioli A, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 2014;4(3):e191.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Leleu X, Moreau P, et al. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. Leukemia. 2021;35(2):562–572.
   PubMed Web of Science ®Google Scholar
• Bringhen S, Pour L, Vorobyev V, et al. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. Leuk Res. 2021;104:106576.
   PubMed Web of Science ®Google Scholar
• Harrison S, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021;194(1):120–131.
   PubMed Web of Science ®Google Scholar
• Schjesvold F, Richardson P, Facon T, et al. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Haematologica. 2021;106(4):1182–1187.
   PubMed Web of Science ®Google Scholar
• Schjesvold F, Bringhen S, Richardson P, et al. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. Am J Hematol. 2021;96(11):E423–E427.
   PubMed Web of Science ®Google Scholar
• Capra M, Martin T, Moreau P, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. Haematologica. 2022;107(6):1397–1409.
   PubMed Web of Science ®Google Scholar
• Spicka I, Moreau P, Martin T, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. Eur J Hematol. 2022;109(5):504–512.
   PubMed Web of Science ®Google Scholar
• Facon T, Moreau P, Martin T, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022;40(5):1020–1029.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Moreau P, Augustson B, et al. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am J Hematol. 2022;98(1):E15–E19.
   PubMed Web of Science ®Google Scholar
• Moreau P, Kumar S, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):E105–E118.
   PubMed Web of Science ®Google Scholar
• Seitzler S, Finley-Oliver E, Simonelli C, et al. Quality of life in multiple myeloma: considerations and recommendations. Expert Rev Hematol. 2019;12(6):419–424.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Campana F, Bury DP, et al. Health-related quality of life in heavily pretreated and renally impaired patients with relapsed/refractory multiple myeloma receiving isatuximab plus pomalidomide and dexamethasone: ICARIA-MM study [abstract no. EP1028]. HemaSphere. 2020;4(Suppl 1):473–474.
   Google Scholar
• Becnel M, Horowitz S, Thomas S, et al. Descriptive analysis of isatuximab use following prior Daratumumab in patients with relapsed/refractory multiple myeloma. Blood. 2020;136(Suppl 1):20–21.
   Google Scholar
• Djebbari F, Poynton M, Sangha G, et al. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. Hematology. 2022;27(1):204–207.
   PubMed Web of Science ®Google Scholar
• Usmani S, Karanes C, Bensinger W, et al. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma. Leukemia. 2021;35(12):3526–3533.
   PubMed Web of Science ®Google Scholar
• Mohan M, Becnel M, Shah U, et al. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: a multi-institutional experience. Am J Hematol. 2022;97(7):E276–E280.
   PubMed Web of Science ®Google Scholar
• Mikhael J, Belhadj-Merzoug K, Hulin C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021;11(5):89.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–1557.
   PubMed Web of Science ®Google Scholar
• Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48:337–341.
   PubMed Web of Science ®Google Scholar